{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:11:34Z","timestamp":1790266294455,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gelu Foundation","award":["-"],"award-info":[{"award-number":["-"]}]},{"name":"PIQUR Therapeutics AG","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The phosphatidylinositol 3-kinase (PI3K)\/AKT\/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1\/2 inhibitor, in 56 lymphoma cell lines. We observed anti-tumor activity across 56 lymphoma models with a median IC50 value of 250 nM after 72 h of exposure. PQR620 was largely cytostatic, but the combination with the BCL2 inhibitor venetoclax led to cytotoxicity. Both the single agent and the combination data were validated in xenograft models. The data support further evaluation of PQR620 as a single agent or in combination with venetoclax.<\/jats:p>","DOI":"10.3390\/cancers11060775","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T09:37:58Z","timestamp":1559727478000},"page":"775","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Novel TORC1\/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-7742","authenticated-orcid":false,"given":"Chiara","family":"Tarantelli","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Universit\u00e0 della Svizzera Italiana, 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Universit\u00e0 della Svizzera Italiana, 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hillmann","sequence":"additional","affiliation":[{"name":"PIQUR Therapeutics AG, 4057 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Spriano","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Universit\u00e0 della Svizzera Italiana, 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Sartori","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Universit\u00e0 della Svizzera Italiana, 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7893-1740","authenticated-orcid":false,"given":"Luca","family":"Aresu","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Veterinarie, Universit\u00e0 degli Studi di Torino, 10095 Grugliasco (TO), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-0637","authenticated-orcid":false,"given":"Luciano","family":"Cascione","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Universit\u00e0 della Svizzera Italiana, 6500 Bellinzona, Switzerland"},{"name":"Swiss Institute of Bioinformatics (SIB), 1015 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Rageot","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Kwee","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Universit\u00e0 della Svizzera Italiana, 6500 Bellinzona, Switzerland"},{"name":"Swiss Institute of Bioinformatics (SIB), 1015 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Beaufils","sequence":"additional","affiliation":[{"name":"PIQUR Therapeutics AG, 4057 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-4281","authenticated-orcid":false,"given":"Matthias P.","family":"Wymann","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Cmiljanovic","sequence":"additional","affiliation":[{"name":"PIQUR Therapeutics AG, 4057 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriano","family":"Fabbro","sequence":"additional","affiliation":[{"name":"PIQUR Therapeutics AG, 4057 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-8983","authenticated-orcid":false,"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Universit\u00e0 della Svizzera Italiana, 6500 Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/bjh.12945","article-title":"Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies","volume":"166","author":"Eyre","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14529","article-title":"m-TOR inhibitors and their potential role in haematological malignancies","volume":"177","author":"Calimeri","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ajh.24671","article-title":"Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma","volume":"92","author":"Bennani","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2017-05-737510","article-title":"The potential for chemotherapy-free strategies in mantle cell lymphoma","volume":"130","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E2721","DOI":"10.1073\/pnas.1406722111","article-title":"BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma","volume":"111","author":"Bhadury","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdx764","article-title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: Final results from the PILLAR-2 randomized phase III trial","volume":"29","author":"Witzig","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1158\/1535-7163.MCT-14-1052","article-title":"CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization","volume":"14","author":"Mortensen","year":"2015","journal-title":"Mol. Cancer. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1535-7163.MCT-14-0711","article-title":"MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma","volume":"14","author":"Slotkin","year":"2015","journal-title":"Mol. Cancer. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1021\/acs.jmedchem.8b01262","article-title":"Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoro methyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1\/2 Inhibitor for Cancer and Neurological Disorders","volume":"61","author":"Rageot","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/cas.13431","article-title":"Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia","volume":"109","author":"Kawata","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.18632\/oncotarget.2337","article-title":"Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors","volume":"5","author":"Hassan","year":"2014","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/bjc.2012.368","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma","volume":"107","author":"Naing","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.24300","article-title":"TAK-228 (formerly MLN0128), an investigational oral dual TORC1\/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom\u2019s macroglobulinemia","volume":"91","author":"Ghobrial","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1002\/cncr.29422","article-title":"A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1\/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma","volume":"121","author":"Bendell","year":"2015","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/bjc.2016.59","article-title":"A first in man, dose-finding study of the mTORC1\/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies","volume":"114","author":"Mateo","year":"2016","journal-title":"Br. J. Cancer."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/13543784.2015.971154","article-title":"Discontinued in 2013: Oncology drugs","volume":"24","author":"Williams","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_21","unstructured":"Tarantelli, C., Gaudio, E., Cascione, L., Stathis, A., Zucca, E., and Bertoni, F. (2018). In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas. Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2141.2012.09113.x","article-title":"Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma","volume":"157","author":"Otto","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_23","first-page":"4227","article-title":"Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models","volume":"9","author":"Pater","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-12-0404","article-title":"The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence","volume":"3","author":"Wall","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2011-01-331421","article-title":"The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines","volume":"119","author":"Lemoine","year":"2012","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1158\/1078-0432.CCR-12-0351","article-title":"Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma","volume":"18","author":"Rosich","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3324\/haematol.2015.130351","article-title":"Co-administration of the mTORC1\/TORC2 inhibitor INK128 and the Bcl-2\/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation","volume":"100","author":"Rahmani","year":"2015","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 Is a Novel Dual PI3K\/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell. Death Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Faia, K., White, K., Murphy, E., Proctor, J., Pink, M., Kosmider, N., McGovern, K., and Kutok, J. (2018). The phosphoinositide-3 kinase (PI3K)-delta, gamma inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200725"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tarantelli, C., Lange, M., Gaudio, E., Cascione, L., Spriano, F., Kwee, I., Arriibas, A., Rinaldi, A., Jourdan, T., and Berthold, M. (2019). Copanlisib synergies with conventional and targeted agents including venetoclax in preclinical models of B- and T-cell lymphomas. Hematol. Oncol., 37, in press.","DOI":"10.1002\/hon.127_2630"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3Kalpha\/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: A phase Ib dose-finding study","volume":"29","author":"Swinnen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: Results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Intracellular signaling pathways: Tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ccr.2013.05.002","article-title":"SYK Inhibition Modulates Distinct PI3K\/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas","volume":"23","author":"Chen","year":"2013","journal-title":"Cancer Cell."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/JME-11-0004","article-title":"Anaplastic lymphoma kinase in human cancer","volume":"47","author":"Barreca","year":"2011","journal-title":"J. Mol. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"72886","DOI":"10.18632\/oncotarget.12128","article-title":"Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma","volume":"7","author":"Redaelli","year":"2016","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-14-3091","article-title":"MEK plus PI3K\/mTORC1\/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer","volume":"21","author":"Rivas","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15802","DOI":"10.18632\/oncotarget.4602","article-title":"p53 and rapamycin are additive","volume":"6","author":"Christy","year":"2015","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K\/mTOR Inhibitor as Clinical Candidate in Oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"14683","DOI":"10.1038\/ncomms14683","article-title":"Deconvolution of Buparlisib\u2019s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention","volume":"8","author":"Bohnacker","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1182\/blood.V128.22.5893.5893","article-title":"A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K\/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma","volume":"128","author":"Collins","year":"2016","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.clml.2016.07.155","article-title":"Targeting mTOR\/PI3K in Primary CNS Lymphoma (PCNSL)","volume":"16","author":"Korfel","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2018-01-791558","article-title":"Novel agents for primary central nervous system lymphoma: Evidence and perspectives","volume":"132","author":"Illerhaus","year":"2018","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.3324\/haematol.2018.207027","article-title":"New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease","volume":"104","author":"Aresu","year":"2019","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.18632\/oncotarget.3239","article-title":"Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response","volume":"6","author":"Mensah","year":"2015","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/6\/775\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:56:12Z","timestamp":1760187372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/6\/775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["cancers11060775"],"URL":"https:\/\/doi.org\/10.3390\/cancers11060775","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]}}}